Systemic sclerosis is a chronic inflammatory disease characterized by severe clinical symptoms which restrict normal daily activities. Gesynta Pharma develops innovative pharmaceuticals with the aim to treat systemic sclerosis and other complex medical conditions.
Gesynta Pharma’s drug candidates utilize a unique mechanism of action to reduce inflammation and pain, and increase blood flow. We are currently developing three drug candidates. One of the compounds has reached clinical phase IIa stage. A second one will start clinical testings in 2022. Read more about our drug development projects.
Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby aiming to provide improved treatments for several serious diseases. In an ongoing clinical phase IIa study, GS-248 is being evaluated for its potential to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program toward additional chronic inflammatory diseases. GS-248 was recently granted Orphan Drug Designation in the US by the FDA for the treatment of systemic sclerosis.
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.
Systemic sclerosis is an autoimmune disease hallmarked by chronic inflammation in the body’s smallest blood vessels.
Raynaud’s phenomenon affects most systemic sclerosis patients. It is often the first sign of the disease.
Half of systemic sclerosis patients develop difficult-to-heal digital ulcers, hampering many everyday activities.
Our lead drug candidate GS-248 is currently under evaluation in a phase 2 study.